Medicare will only pay if patients have potentially serious heart problems.
Wegovy is the brand name of Novo Nordisks anti-obesity medication semaglutide, first approved in the U.S. in 2021.
That change will help about1 million seniorswho pay for incredibly costly drugs commonly used in cancer patients.
Photo: Michael Siluk/UCG/Universal Images Group (Getty Images)
Collaboration across the healthcare system is key to educate and to broaden coverage of obesity medicines.
News from the future, delivered to your present.
